Is Low Positive JAK2 V617F Mutation Test Result Clinically Significant?: Multi-Institutional Study
Publication Date
2015
Journal Title
Appl Immunohistochem Mol Morphol
Abstract
OBJECTIVES: Acquired somatic mutation Janus kinase 2 (JAK2) V617F is associated with various myeloproliferative neoplasms (MPN). Allele-specific real-time polymerase chain reaction has been widely adopted to detect mutation; however, the utility of low positive results is not well understood. The aim of this study is to investigate the clinical significance of low positivity of JAK2 V617F. MATERIALS AND METHODS: Retrospective analysis was performed for JAK2 V617F mutation tests performed using JAK2 MutaQuant kit (Ipsogen) in molecular laboratories at 2 major academic medical centers between 2010 and 2012. Cases with low positive JAK2 V617F, defined as 0.2% to 5% mutant allele, were documented. Chart review was performed for the clinical correlation. RESULTS: A total of 1697 JAK2 V617F tests was performed. Forty-five cases (2.65%) yielded a low JAK2 V617F positivity (average 1.45%), the majority of which (n=26, 62%) had
Volume Number
24
Issue Number
8
Pages
589-94
Document Type
Article
EPub Date
2015/09/16
Status
Faculty, Northwell Researcher
Facility
School of Medicine; Northwell Health
Primary Department
Pathology and Laboratory Medicine
PMID
DOI
10.1097/pai.0000000000000228